Moonlake Immunotherapeutics Quick Ratio (MLTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Moonlake Immunotherapeutics  (NASDAQ: MLTX)

Moonlake Immunotherapeutics's Quick Ratio

MLTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Moonlake Immunotherapeutics's Cash & cash equivalent grew by 50.03 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Moonlake Immunotherapeutics's Quick Ratio to 11.83, Quick Ratio remained below Moonlake Immunotherapeutics average.

Within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Quick Ratio than Moonlake Immunotherapeutics in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 0 to 336.

Explain Quick Ratio?
How much Cash & cash equivalents MLTX´s has?
What are MLTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MLTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 65.9 % 92.29 % 102.45 % 140.86 % 122.77 %
Y / Y Cash & cash equivalent Change 26.33 % -25.45 % -12.07 % -22.97 % -18.22 %
Quick Ratio MRQ 11.83 7.76 8.66 7.87 15.54
MLTX's Total Ranking # 336 # 0 # 205 # 347 # 162
Seq. Current Liabilities Change -1.57 % 1.4 % -5.98 % 76.78 % 14.09 %
Seq. Cash & cash equivalent Change 50.03 % -9.15 % 3.55 % -10.49 % -11.47 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 91
Healthcare Sector # 132
Overall Market # 336


Quick Ratio Statistics
High Average Low
70.33 21.64 0
(Jun 30 2023)   (Mar 31 2022)




Financial Statements
Moonlake Immunotherapeutics's Current Liabilities $ 45 Millions Visit MLTX's Balance sheet
Moonlake Immunotherapeutics's Cash & cash equivalent $ 537 Millions Visit MLTX's Balance sheet
Source of MLTX's Sales Visit MLTX's Sales by Geography


Cumulative Moonlake Immunotherapeutics's Quick Ratio

MLTX's Quick Ratio for the trailling 12 Months

MLTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 97.42 % 112.32 % 127.79 % 138.44 % 126.42 %
Y / Y Cash & cash equivalent TTM Growth -9.63 % -19.8 % -16.39 % -16.32 % -10.93 %
Quick Ratio TTM 9.01 9.31 11.57 14.19 19.67
Total Ranking TTM # 3392 # 0 # 1802 # 2315 # 2083
Seq. Current Liabilities TTM Growth 10.78 % 15.24 % 18.84 % 30.13 % 19.13 %
Seq. Cash & cash equivalent TTM Growth 7.19 % -7.28 % -3.12 % -6.14 % -4.88 %

Quick ratio ranking by company, industry and sector >> Back to MLTX Financial Strength Comparisons >> Go to Compare MLTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2026 to $45.39 millions, cumulative Quick Ratio decreased to 9.01 below the Moonlake Immunotherapeutics average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Moonlake Immunotherapeutics. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 0 to 3392.

Explain Quick Ratio?
How much Cash & cash equivalents MLTX´s has?
What are MLTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 415
Healthcare Sector # 844
Within the Market # 3392


trailing twelve months Quick Ratio Statistics
High Average Low
56.61 19.98 0.01
(Mar 31 2024)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions
Kailera Therapeutics Inc   23.41 $ 1,958.240  Millions$ 83.651  Millions
Equillium Inc   23.07 $ 57.164  Millions$ 2.478  Millions
Relmada Therapeutics Inc  21.72 $ 217.731  Millions$ 10.023  Millions
Keros Therapeutics Inc   21.20 $ 257.606  Millions$ 12.153  Millions
Protagonist Therapeutics inc   21.05 $ 782.576  Millions$ 37.181  Millions

Date modified: 2026-09-26T07:40:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.